Treeline Biosciences, Inc.
Clinical trials sponsored by Treeline Biosciences, Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill takes on tough lymphoma: early trial seeks tumor shrinkage Results expected Nov 2026 (estimated)
-
New hope for tough lymphomas: experimental drug TLN-121 enters human testing
Disease control Recruiting nowThis early-stage trial is testing a new drug called TLN-121, alone or with other medicines, in about 180 people whose Non-Hodgkin Lymphoma has returned or stopped responding to prior treatments. The main goals are to check the drug's safety and how the body processes it, while al…
Phase 1 • Sponsor: Treeline Biosciences, Inc. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New drug targets tough KRAS cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called TLN-372 in people with advanced solid tumors that have a KRAS mutation. The goal is to check the drug's safety and how well it works, both alone and with other cancer treatments. About 240 adults with measurable, advanced or metastat…
Phase 1 • Sponsor: Treeline Biosciences, Inc. • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC